Homoplantaginin inhibits palmitic acid-induced endothelial cells inflammation by suppressing TLR4 and NLRP3 inflammasome

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 1, 2016, Pages 93-101

  He, Baiqiu ^a   Zhang, Baobao ^a   Wu, Feihua ^a   Wang, Liying ^a   Shi, Xiaoji ^a   Qin, Weiwei ^a   Lin, Yining ^a   Ma, Shiping ^a   Liang, Jingyu ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

homoplantaginin; NLRP3 inflammasome; palmitic acid; TLR4; vascular endothelial cells

Indexed keywords

ANTIINFLAMMATORY AGENT; CRYOPYRIN; FLAVONOID; HOMOPLANTAGININ; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; PALMITIC ACID; REACTIVE OXYGEN METABOLITE; THIOREDOXIN INTERACTING PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; 6-METHOXY-4',5-DIHYDROXYFLAVONE-7-O-GLUCOSIDE; CARRIER PROTEIN; GLUCOSIDE; HERBACEOUS AGENT; NLRP3 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASCULITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; INFLAMMATION; ISOLATION AND PURIFICATION; METABOLISM; SALVIA MILTIORRHIZA;

CARRIER PROTEINS; DRUGS, CHINESE HERBAL; FLAVONOIDS; GLUCOSIDES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMASOMES; INFLAMMATION; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PALMITIC ACID; SALVIA MILTIORRHIZA; TOLL-LIKE RECEPTOR 4;

EID: 84954466387     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000318     Document Type: Article

References (49)

1. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009;20:295-302.
2. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev. 2010;9:830-834.
3. Griendling KK, Sorescu D, Ushio FM. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
4. Mehta JL, Li D. Identification, regulation and function of a novel lectinlike oxidized low-density lipoprotein receptor. J Am Coll Cardiol. 2002; 39:1429-1434.
5. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-1160.
6. Tousoulis D, Simopoulou C, Papageorigou N, et al. Endothelial dysfunction in conduit and microcirculation. Novel therapeutic approaches. Pharmacol Ther. 2014;144:253-267.
7. Galder PC. Long chain fatty acids and gene expression in inflammation and immunity. Curr Opin Clin Nutr Metab Care. 2013;16:425-433.
8. Lee SM, Choi SE, Lee JH, et al. Involvement of the TLR4 (toll-like receptor 4) signaling pathway in palmitate-induced INS-1 beta cell death. Mol Cell Biochem. 2011;354:207-217.
9. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56:1986-1998.
10. Huang S, Rutkowaky JM, Snodgrass RG, et al. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res. 2012;53:2002-2013.
11. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015-3025.
12. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012;413:3-14.
13. Xie P. TRAF molecules in cells signaling and in human diseases. J Mol Signal. 2013;8:7.
14. Wu H, Arron J. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays. 2003;25:1096-1105.
15. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493:346-355.
16. Wen H, Gris D, Jha S, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12:408-415.
17. Zhou R, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221-225.
18. Chamberlain J, Francis S, Brookes Z, et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. Plos One. 2009;4:1-9.
19. Ding P, Tian YQ. Study progress on the Chinese herb Salvia plebeia R. BR. J Anhui Agri Sci. 2008;36:4133-4134.
20. Qu XJ, Xia X, Wang YS, et al. Protective effects of Salvia plebeia compound homoplantaginin on hepatocyte injury. Food Chem Toxicol. 2009;47:1710-1715.
21. Wu FH, Liang JH, Wang H, et al. Antidiabetic flavonoids and their usage. China Patent Number 201110024707. 2.
22. Park SH, Kim JL, Kang MK, et al. Sage weed (Salvia plebeia) extract antagonizes foam cell formation and promotes cholesterol efflux in murine macrophages. Int J Mol Med. 2012;30:1105-1112.
23. Wu FH, Wang H, Li J, et al. Homoplantaginin modulates insulin sensitivity in endothelial cells by inhibiting inflammation. Biol Pharm Bull. 2012;35:1171-1177.
24. Wang H, He BQ, Wang LY, et al. Protective effect of homoplantaginin on endothelial cells apoptosis induced by palmitic acid. Pharmacol Clin Chin Mater Med. 2014;30:39-42.
25. Peng N, Liu JT, Guo F, et al. Epigallocatechin-3-gallate inhibits interleukin-6- and angiotensin II-induced production of C-reactive protein in vascular smooth muscle cells. Life Sci. 2010;86:410-415.
26. Libby P. Molecular and cellular mechanisms of the thrombotic complication of atherosclerosis. J Lipid Res. 2009;50:S352-S357.
27. Goldberg IJ, Bornfeldt KE. Lipids and the endothelium: bidirectional interactions. Curr Atheroscler Rep. 2013;15:365-372.
28. Yli-Jama P, Meyer HE, Ringstad J, et al. Serum free fatty acid pattern and risk of myocardial infarction: a case-control study. J Intern Med. 2002;251:19-28.
29. Knopp RH, Retzlaff B, Walden C, et al. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in freeliving subjects. Proc Soc Exp Biol Med. 2000;225:191-199.
30. Artwohl M, Roden M, Waldhausl W, et al. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. Faseb J. 2004;18:146-148.
31. Wu JJ, Xu XS, Li Y, et al. Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells. Eur J Pharmacol. 2014;745:59-68.
32. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
33. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801.
34. West AP, Brodsky IE, Rashner C, et al. TLR signaling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011; 472:476-480.
35. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361.
36. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166:1-15.
37. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro IL-beta. Mol Cell. 2002;10:417-426.
38. Song JN, Li J, Hou FJ, et al. Mangiferin inhibits endoplasmic reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome activation with regulation of AMPK in endothelial cells. Metabolism. 2015;64:428-437.
39. Mohamed IN, Hafez SS, Fairaq A, et al. Thioredoxin-interacting protein is required for endothelial nlrp3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia. 2014;57:413-423.
40. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787-791.
41. Juliana C, Fernandes-Alnemri T, Kang S, et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. 2012;287:36617-36622.
42. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996; 87:2095-2147.
43. Navi A, Patel H, Shaw S, et al. Therapeutic role of toll-like receptor modification in cardiovascular dysfunction. Vasc Pharmacol. 2013;58: 231-239.
44. Merhi SF, Kwak BR, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apoliporotein E-knockout mice. Cardiovasc Res. 2005;66:583-593.
45. Luheshi NM, Rothwell NJ, Brough. Dual functionality of interleukin-1 family cytokines implications fFproinflammr anti-interleukin-1 therapy. Br J Pharmacol. 2009;157:1318-1329.
46. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-652.
47. Yang L, Froio RM, Sciuto TE, et al. ICAM-1 regulates adhesion and transcellular migration of TNF-a-activated vascular endothelium under flow. Blood. 2005;106:584-592.
48. Dashmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1(MCP-1): an overview. J Interferon Cytokine Res. 2009;29: 313-326.
49. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-837.